TS013(TS013) - 药物靶点：GLO1_在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

GLO1

作用机制

GLO1 inhibitors(glyoxalase I inhibitors)

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症-

原研机构

Jordan University of Science & Technology

在研机构

Jordan University of Science & Technology

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C16H12N4O5S

InChIKeyLELBGRSOXHYESE-FMQUCBEESA-N

CAS号2914127-33-4

关联

100 项与 TS013 相关的临床结果

登录后查看更多信息

100 项与 TS013 相关的转化医学

登录后查看更多信息

100 项与 TS013 相关的专利（医药）

登录后查看更多信息

1

项与 TS013 相关的文献（医药）

2024-06-01·Bulletin of Experimental Biology and Medicine

Redox-Active Compounds in the Therapy of Drug-Resistant Murine Leukemia P388 Strains

Article

作者: Raevskaya, T A ; Faingold, I I ; Soldatova, Yu V ; Goncharova, S A

The efficiency of combinations of cytostatics cisplatin and adriamycin with antioxidant sodium 3-(3'-tert-butyl-4-hydroxyphenyl)propyl thiosulfate (TS-13), and nitric oxide (NO) donor NaNO₂ was evaluated on two drug-resistant strains of leukemia P388 with changed redox-status of cells. Simultaneous use of both NO donor and TS-13 in combinations with the cytostatics did not increase the efficiency of therapy. In addition, antioxidant activity of TS-13, NaNO₂, and their combinations was studied by the method of luminol-dependent chemiluminescence on the model systems with the use of the homogenized cells of sensitive strain and two drug-resistant strains of leukemia P388. It was shown that TS-13 and NO donor produced opposite effects: TS-13 decreased, while NO donor increased the content of free radicals in the model system. Combinations of antioxidant TS-13 and NO donor should be used with consideration for the redox-status of tumor treated.

100 项与 TS013 相关的药物交易

登录后查看更多信息